Top 10 Companies in the Plant-based Hemostat Powder Market (2026): Market Leaders Driving Innovation

The Plant-based Hemostat Powder market pertains to surgical hemostatic agents made from purified plant starch that are used to control bleeding in surgical and wound care applications. These powders, which are derived from natural plant-based sources, serve as a reliable alternative to synthetic hemostatic agents. The powders are known for their quick ability to stop bleeding by promoting clotting and sealing blood vessels, making them essential in both emergency and elective surgical procedures.

The growing shift toward natural and plant-based materials in the medical sector, alongside increasing preferences for eco-friendly and biocompatible medical products, has contributed to the rising demand for plant-based hemostat powders.

Plant-based Hemostat Powder Market – View in Detailed Research Report

Market Size

Global Plant-based Hemostat Powder market was valued at USD 174.30 million in 2025 and is projected to reach USD 251.87 million by 2034, reflecting a compound annual growth rate of 5.40%. The expansion is driven by the rise in minimally invasive procedures, increasing healthcare expenditure, and a broader move toward sustainable medical solutions.

In North America, the market was valued at USD 45.42 million in 2025, with a forecasted CAGR of 4.63% through 2034, underpinned by technological advances, chronic disease prevalence, and the adoption of plant-based products.

Product Definition

Plant-based hemostat powders are formulated from purified plant starches that accelerate clot formation and seal blood vessels during surgical and wound care interventions. Their rapid action, biocompatibility, and lower environmental footprint make them attractive alternatives to synthetic agents.

Top 10 Companies in the Plant-based Hemostat Powder Market

🔟 1. Johnson & Johnson

Headquarters: New Brunswick, New Jersey, USA
Key Offering: SurgiSeal Plant-Based Hemostat Powder (3g)

Johnson & Johnson has leveraged its extensive research base to introduce SurgiSeal, a plant-derived hemostatic agent that demonstrates rapid clotting and low inflammatory response. The product is marketed to hospitals and surgical centers that prioritize eco-friendly protocols.

Sustainability Initiatives:

Committed to sourcing 100% renewable raw materials by 2030.
Partnered with agricultural cooperatives to secure sustainable starch supply chains.
Implemented carbon-neutral manufacturing processes across its North American facilities.

9️⃣ 2. Ethicon

Headquarters: South San Francisco, California, USA
Key Offering: BioHem Plant-Based Hemostat (1g & 5g)

Ethicon’s BioHem delivers consistent hemostatic performance while maintaining a minimal ecological footprint. Its modular packaging supports both elective and emergency scenarios, positioning it as a versatile solution for surgeons worldwide.

Growth Initiatives:

Investing in plant-based polymer research to enhance clotting efficiency.
Expanding distribution to emerging markets in Asia‑Pacific.
Collaborating with regulatory bodies to streamline approval pathways for natural products.

8️⃣ 3. Baxter

Headquarters: Deerfield, Illinois, USA
Key Offering: PlantStarch Hemostat Powder (3g)

Baxter’s PlantStarch is engineered to provide rapid hemostasis with a low risk of infection, making it suitable for complex surgeries. The company emphasizes quality control and traceability throughout its supply chain.

Innovation Focus:

Developing hybrid formulations that combine plant starch with bioactive peptides.
Investing in advanced imaging to monitor clot formation in real time.
Expanding R&D collaborations with universities in Europe.

7️⃣ 4. Celox

Headquarters: Houston, Texas, USA
Key Offering: Celox-Plant Hemostat (5g)

Celox has introduced a plant-based variant that retains its hallmark rapid clotting while reducing synthetic content. The product is marketed to both civilian and military medical facilities.

Strategic Moves:

Secured a joint venture with a South American starch supplier.
Launching a digital platform for real-time supply chain monitoring.
Expanding product line to include trauma dressings infused with plant-based hemostatics.

6️⃣ 5. BD

Headquarters: Billerica, Massachusetts, USA
Key Offering: BD Plant-Based Hemostat (1g)

BD’s plant-based powder is designed for rapid application in laparoscopic procedures, offering a low‑adherence profile that eases postoperative care.

Key Initiatives:

Investing in AI-driven analytics to predict hemostatic performance.
Partnering with global health NGOs to distribute products in low‑resource settings.
Enhancing packaging sustainability with biodegradable materials.

5️⃣ 6. Biocer

Headquarters: Shanghai, China
Key Offering: Biocer Plant Hemostat (3g)

Biocer focuses on leveraging local agricultural resources to produce high‑purity starch powders. Its product line caters to the rapidly growing Chinese surgical market.

Growth Strategy:

Expanding production capacity in Tier‑2 cities.
Collaborating with national health ministries to standardize plant-based hemostatics.
Investing in biodegradable packaging solutions.

4️⃣ 7. Hemostasis

Headquarters: Moscow, Russia
Key Offering: Hemostasis Plant Powder (5g)

Hemostasis offers a plant-derived powder that meets stringent European safety standards, positioning it as a preferred choice in the EU market.

Key Actions:

Establishing a regional R&D hub in Berlin.
Securing EU certification for environmental compliance.
Expanding distribution to Eastern European countries.

3️⃣ 8. Grena

Headquarters: Milan, Italy
Key Offering: Grena Plant-Based Hemostat (1g & 3g)

Grena’s products are known for their low allergenic potential and are marketed across hospitals in the Mediterranean region.

Development Focus:

Investing in plant breeding programs to enhance starch yield.
Partnering with EU research institutes for clinical trials.
Developing a smart packaging system to preserve sterility.

2️⃣ 9. Smith & Nephew

Headquarters: London, United Kingdom
Key Offering: Smith Plant Hemostat (3g)

Smith & Nephew’s plant-based powder offers a balance of rapid clotting and low cost, making it attractive for public healthcare systems.

Strategic Highlights:

Launching a pilot program in the NHS to evaluate cost‑effectiveness.
Investing in regenerative agriculture to secure raw material supply.
Expanding into the German market through joint ventures.

1️⃣ 10. B. Braun

Headquarters: Melsungen, Germany
Key Offering: B. Braun Plant Hemostat (5g)

B. Braun’s plant-based powder is engineered for high‑volume surgical settings, providing consistent performance across a range of procedures.

Innovation Path:

Integrating digital tracking for real‑time supply chain visibility.
Partnering with Nordic universities for advanced material research.
Expanding distribution to Scandinavian and Baltic markets.

Download FREE Sample Report: Plant-based Hemostat Powder Market – View in Detailed Research Report

Get Full Report: Plant-based Hemostat Powder Market – View in Detailed Research Report

🌍 Outlook: The Future of Plant-based Hemostat Powder Is Cleaner and Smarter

The market is set to evolve as healthcare providers increasingly prioritize sustainability. Plant-based powders are expected to gain traction in both elective and emergency settings, driven by evidence of comparable efficacy to synthetic counterparts and lower environmental impact.

📈 Key Trends Shaping the Market:

Expansion of plant-based formulations into trauma and post‑operative care.
Adoption of digital supply chain tools to mitigate raw‑material volatility.
Strategic alliances between pharmaceutical and agricultural sectors.
Increased regulatory focus on natural product safety and efficacy.

🔮 Future Trends

Emerging research into bio‑engineered starches and nano‑carrier systems may unlock new performance thresholds for plant-based hemostats. Additionally, global health initiatives targeting low‑resource environments will likely accelerate the adoption of affordable, sustainable bleeding‑control solutions.

Author
Recent Posts

Rohit k